Hepatology
Page 1 • 4 itemsGain critical insights into the global hepatology drug market. Track R&D, regulatory approvals, and investment opportunities in liver disease therapeutics.
X4 Pharmaceuticals Receives European Commission Approval for XOLREMDI (Mavorixafor) as First WHIM Syndrome Treatment in EU
X4 Pharmaceuticals announces European Commission approval for XOLREMDI (mavorixafor), the first authorized treatment for WHIM syndrome patients in the EU.
Artiva Biotherapeutics' AlloNK Receives FDA Fast Track Designation for Refractory Rheumatoid Arthritis Treatment
FDA grants Fast Track Designation to Artiva's AlloNK (AB-101) for refractory rheumatoid arthritis, accelerating development of innovative NK cell therapy.
Opella's Essentiale Shows 2.5x Greater Liver Fat Reduction in Breakthrough EXCEL Trial for Fatty Liver Disease
Opella's Essentiale essential phospholipids demonstrated 2.5 times greater liver fat reduction vs diet/exercise alone in MASLD patients in EXCEL trial.
Brii Bio's Elebsiran Shows Durable Hepatitis B Control in APASL 2026 Cross-Study Analysis
Brii Bio's elebsiran combined with pegylated interferon demonstrates sustained HBsAg loss and favorable off-treatment outcomes in hepatitis B patients.